Definium Therapeutics, Inc. Common Shares (DFTX)
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Definium Therapeutics, Inc. Common Shares (DFTX) is listed on Nasdaq, where it has traded since March 3, 2020.
- Listed On
- Nasdaq
- Listed Since
- March 3, 2020
- Employees
- 106
- Market Cap
- $5.1B
About Definium Therapeutics, Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 348 institutions reported holding DFTX, with 114.8 million shares worth $5.3 billion in aggregate. The largest reported holder was BlackRock, with 11.2 million shares worth $528.4 million. Of the 5 largest holders listed below, 2 opened new positions in DFTX and 3 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 11,232,834 | $528M | Added 32.46% |
| Capital Group | 8,331,133 | $392M | New position |
| Avoro Capital Advisors | 7,188,888 | $338M | Added 43.78% |
| Driehaus Capital Management | 6,845,276 | $322M | Added 15.79% |
| Jupiter Topco | 5,615,645 | $264M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is DFTX?
Definium Therapeutics, Inc. Common Shares (DFTX) is listed on Nasdaq, where it has traded since March 3, 2020.
Who are the largest institutional holders of DFTX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of DFTX were BlackRock, Capital Group and Avoro Capital Advisors.
How many institutions own DFTX?
348 institutions reported a position in DFTX for the quarter ended June 30, 2026, worth $5.3 billion in total.
Did institutions buy or sell DFTX last quarter?
Of the 5 largest reported holders, 2 opened new positions in DFTX and 3 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for DFTX.
Every reported institutional holder, plus insider and congressional trades in DFTX, on SentiSense.